title: Photodynamic therapy with 3-(1'-hexyloxyethyl) pyropheophorbide-a for early-stage cancer of the larynx: Phase Ib study.
abstract: The purpose of this study was for us to report results regarding the safety of 3-(1'-hexyloxyethyl) pyropheophorbide-a (HPPH) mediated photodynamic therapy (PDT) in early laryngeal disease, and offer preliminary information on treatment responses.
  
  
  
  A single-institution, phase Ib, open label, noncomparative study of HPPH-PDT in patients with high-risk dysplasia, carcinoma in situ, and T1 squamous cell carcinoma (SCC) of the larynx. The primary outcomes were safety and maximum tolerated dose (MTD), and the secondary outcome was response.
  
  
  
  Twenty-nine patients and 30 lesions were treated. The most common adverse event (AE) was transient hoarseness of voice. Severe edema, requiring tracheostomy, was the most serious AE, which occurred in 2 patients within several hours of therapy. The MTD was 100 J/cm(2) . Patients with T1 SCC seemed to have good complete response rate (82%) to HPPH-PDT at MTD.
  
  
  
  HPPH-PDT can be safely used to treat early-stage laryngeal cancer, with potential efficacy. © 2015 The Authors Head & Neck Published by Wiley Periodicals, Inc. Head Neck 38: E377-E383, 2016.
authors.affiliation: Photodynamic Therapy Center, Roswell Park Cancer Institute, Buffalo, New York.|Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York.|Department of Head and Neck Surgery, Roswell Park Cancer Institute, Buffalo, New York.
authors.forename: Gal
authors.initials: G
authors.lastname: Shafirstein
authors.affiliation: Photodynamic Therapy Center, Roswell Park Cancer Institute, Buffalo, New York.
authors.forename: Nestor R
authors.initials: NR
authors.lastname: Rigual
authors.affiliation: Photodynamic Therapy Center, Roswell Park Cancer Institute, Buffalo, New York.|Department of Head and Neck Surgery, Roswell Park Cancer Institute, Buffalo, New York.
authors.forename: Hassan
authors.initials: H
authors.lastname: Arshad
authors.affiliation: Photodynamic Therapy Center, Roswell Park Cancer Institute, Buffalo, New York.
authors.forename: Michele T
authors.initials: MT
authors.lastname: Cooper
authors.affiliation: Photodynamic Therapy Center, Roswell Park Cancer Institute, Buffalo, New York.|Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York.
authors.forename: David A
authors.initials: DA
authors.lastname: Bellnier
authors.affiliation: Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York.
authors.forename: Gregory
authors.initials: G
authors.lastname: Wilding
authors.affiliation: Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York.
authors.forename: Wei
authors.initials: W
authors.lastname: Tan
authors.affiliation: Department of Pathology, Roswell Park Cancer Institute, Buffalo, New York.
authors.forename: Mihai
authors.initials: M
authors.lastname: Merzianu
authors.affiliation: Photodynamic Therapy Center, Roswell Park Cancer Institute, Buffalo, New York.
authors.forename: Barbara W
authors.initials: BW
authors.lastname: Henderson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002278:Carcinoma in Situ / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*
chemical_list: D017319:Photosensitizing Agents
keywords: carcinoma in situ; dysplasia; larynx; photodynamic therapy; squamous cell carcinoma